Skip to main content
TipRanks
Go Ultimate75% OFF

ADARx Pharmaceuticals (ADRX) Stock Statistics & Valuation Metrics

9 Followers

Total Valuation

ADARx Pharmaceuticals has a market cap or net worth of $1.54B. The enterprise value is $1.24B.

Market Cap
$1.54B
Enterprise Value
$1.24B

Share Statistics

ADARx Pharmaceuticals has 111,193,440 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
111,193,440
Owned by Insiders
29.02%
Owned by Institutions
57.69%

Financial Efficiency

ADARx Pharmaceuticals’s return on equity (ROE) is 0.36 and return on invested capital (ROIC) is -18.45%.

Return on Equity (ROE)
0.36
Return on Assets (ROA)
-0.14
Return on Invested Capital (ROIC)
-18.45%
Return on Capital Employed (ROCE)
-0.19
Revenue Per Employee
34.49K
Profits Per Employee
-730.88K
Employee Count
100
Asset Turnover
0.01
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of ADARx Pharmaceuticals is -5.66. ADARx Pharmaceuticals’s PEG ratio is 0.17.

PE Ratio
-5.66
PS Ratio
229.52
PB Ratio
2.60
Price to FCF
-15.85
Price to Operating Cash Flow
-15.57
PEG Ratio
0.17

Income Statement

In the last 12 months, ADARx Pharmaceuticals had revenue of 3.45M and earned -73.09M in profits. Earnings per share was -0.97.

Revenue
3.45M
Gross Profit
3.45M
Operating Income
-88.36M
Pretax Income
-73.09M
Net Income
-73.09M
EBITDA
-86.04M
Earnings Per Share (EPS)
-0.97

Cash Flow

In the last 12 months, operating cash flow was -95.97M and capital expenditures -1.36M, giving a free cash flow of -97.34M billion.

Operating Cash Flow
-95.97M
Free Cash Flow
-97.34M
Free Cash Flow per Share
-0.91

Dividends & Yields

ADARx Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-6.39%
Earnings Yield
-6.52%

Stock Price Statistics

Beta
3.84
52-Week Price Change
-28.58%
50-Day Moving Average
17.13
200-Day Moving Average
17.13
Relative Strength Index (RSI)
34.07
Average Volume (3m)
651.48K

Important Dates

ADARx Pharmaceuticals upcoming earnings date is ―, After Close (Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
―
Ex-Dividend Date
―

Financial Position

ADARx Pharmaceuticals as a current ratio of 16.18, with Debt / Equity ratio of -3.83%

Current Ratio
16.18
Quick Ratio
16.18
Debt to Market Cap
0.00
Net Debt to EBITDA
0.68
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, ADARx Pharmaceuticals has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

ADARx Pharmaceuticals EV to EBITDA ratio is -8.63, with an EV/FCF ratio of -9.86.

EV to Sales
142.81
EV to EBITDA
-8.63
EV to Free Cash Flow
-9.86
EV to Operating Cash Flow
-10.00

Balance Sheet

ADARx Pharmaceuticals has $901.01M in cash and marketable securities with $6.46M in debt, giving a net cash position of $894.55M billion.

Cash & Marketable Securities
$901.01M
Total Debt
$6.46M
Net Cash
$894.55M
Net Cash Per Share
$8.04
Tangible Book Value Per Share
$5.36

Margins

Gross margin is -231.03%, with operating margin of -1692.59%, and net profit margin of -1431.77%.

Gross Margin
-231.03%
Operating Margin
-1692.59%
Pretax Margin
-1431.77%
Net Profit Margin
-1431.77%
EBITDA Margin
-1655.60%
EBIT Margin
-1692.59%

Analyst Forecast

The average price target for ADARx Pharmaceuticals is $35.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$35.00
Price Target Upside
153.26% Upside
Analyst Consensus
Strong Buy
Analyst Count
4
Revenue Growth Forecast
―
EPS Growth Forecast
―

Scores

Smart Score
10
AI Score
―